All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Andrew Davies, BSc, BM, FRCP, PhD, is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton, Southampton, UK. He completed his training in Medical Oncology at St Bartholomew’s Hospital, London, UK, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.
Professor Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first-in-man lymphoma studies.
He is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex Regional Lead for Cancers in Teenagers and Young Adults.
Positions of responsibility: